



## ASX Announcement

15 October 2024

# CEO Acquires Additional Shares Demonstrating Strong Confidence in the Company

**Sydney, Australia; 15 October 2024:** Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium, CMB or Company**), a clinical-stage regenerative medicine company developing innovative biologics for ophthalmology and tissue repair applications, is pleased to announce that CEO Karolis Rosickas has acquired an additional 38,717 shares of CMB in the open market during the trading window following the release of the Company's Annual Report 2024. This purchase was completed in accordance with Cambium Bio's Securities Trading Policy and brings Mr. Rosickas' total shareholding to 77,080 shares, representing approximately 0.65% of the Company's outstanding share capital.

This recent purchase by the CEO is a clear demonstration of Mr. Rosickas' strong confidence in the future of Cambium Bio and its lead clinical asset, Elate Ocular<sup>®</sup>, which is planned to enter Phase 3 clinical trials. Elate Ocular<sup>®</sup> is being developed to address significant unmet medical needs in the treatment of dry eye disease, a condition affecting hundreds of millions worldwide.

Karolis Rosickas' increased investment in Cambium Bio underscores his belief in the Company's proprietary technologies, including Elate Ocular<sup>®</sup>, and its potential to bring transformative therapies to patients in need. The executive team remains focused on advancing the clinical pipeline.

"My decision to increase my personal shareholding reflects my belief in Cambium Bio's potential to deliver significant value to patients, clinicians, and shareholders alike," said Mr. Rosickas. "With our lead product, Elate Ocular<sup>®</sup>, advancing into Phase 3 trials, we are well-positioned to address the substantial unmet needs in dry eye disease and beyond."

The Company remains committed to executing on its strategic plan, advancing its innovative product pipeline through clinical development, and ultimately improving patient outcomes. Cambium Bio believes that the CEO's increased shareholding further aligns the interests of leadership with those of all shareholders, and demonstrates the high level of confidence in the Company's direction and growth prospects.

**About Cambium Bio Limited**

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit [www.cambium.bio](http://www.cambium.bio)

- ENDS -

**Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Helen Leung  
Corporate Secretary  
[info@cambium.bio](mailto:info@cambium.bio)  
1 300 995 098